B
Bryce P. Portier
Researcher at Cleveland Clinic
Publications - 32
Citations - 1403
Bryce P. Portier is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 17, co-authored 30 publications receiving 1236 citations. Previous affiliations of Bryce P. Portier include Cleveland Clinic Lerner College of Medicine & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
Warren Fiskus,Sunil Sharma,Bhavin Shah,Bryce P. Portier,Santhana G. T. Devaraj,Ka Liu,Swaminathan P. Iyer,David J. Bearss,Kapil N. Bhalla +8 more
TL;DR: The combination of LSD1 antagonist and pan-HDI is a promising therapy warranting further testing against AML, and co-treatment with SP2509 and PS significantly improved the survival of the mice engrafted with the human AML cells, without exhibiting any toxicity.
Journal ArticleDOI
Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics
Rashmi Kanagal-Shamanna,Bryce P. Portier,Rajesh R. Singh,Mark J. Routbort,Kenneth D. Aldape,Brian Handal,Hamed Rahimi,Neelima Reddy,Bedia A. Barkoh,Bal Mukund Mishra,Abhaya Paladugu,Jawad Manekia,Neda Kalhor,Sinchita Roy Chowdhuri,Gregg A Staerkel,L. Jeffrey Medeiros,Rajyalakshmi Luthra,Keyur P. Patel +17 more
TL;DR: Next-generation sequencing can be performed with only nanograms of DNA and has better sensitivity than traditional sequencing platforms and enhances the power of fine needle aspiration by providing gene mutation results that can direct personalized cancer therapy.
Journal ArticleDOI
Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
Warren Fiskus,Sunil Sharma,Jun Qi,John A Valenta,Leasha J. Schaub,Bhavin Shah,Karissa Peth,Bryce P. Portier,Melissa Rodriguez,Santhana G. T. Devaraj,Ming Zhan,Jianting Sheng,Swaminathan P. Iyer,James E. Bradner,Kapil N. Bhalla +14 more
TL;DR: The sensitizing effects of the histone hyperacetylation-inducing pan–histone deacetylase (HDAC) inhibitor panobinostat on human acute myelogenous leukemia (AML) blast progenitor cells (BPC) to the BET protein antagonist JQ1 are demonstrated.
Journal ArticleDOI
BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
Warren Fiskus,Sunil Sharma,Jun Qi,Bhavin Shah,Santhana G. T. Devaraj,Christopher Leveque,Bryce P. Portier,Swaminathan P. Iyer,James E. Bradner,Kapil N. Bhalla +9 more
TL;DR: It is demonstrated that cotreatment with JQ1 and the FLT3 tyrosine kinase inhibitor (TKI) ponatinib or AC220 synergistically induce apoptosis of cultured and primary CD34+ human AML blast progenitor cells (BPC) expressingFLT3-ITD.
Journal ArticleDOI
ALK Status Testing in Non–Small Cell Lung Carcinoma: Correlation Between Ultrasensitive IHC and FISH
Eugen C. Minca,Bryce P. Portier,Zhen Wang,Christopher Lanigan,Carol Farver,Yan Feng,Patrick C. Ma,Valeria Arrossi,Nathan A. Pennell,Raymond R. Tubbs +9 more
TL;DR: IHC demonstrated 100% sensitivity and specificity for ALK detection on 249 dual-informative NSCLC samples, and warrants its routine use as the initial component of an algorithmic approach to clinical ALK testing in NSCLc, followed by reflex FISH confirmation of IHC-positive cases.